News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVRBF): Simeprevir Has Now Been Approved In Russia


3/24/2014 10:58:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Medivir AB (STO:MVIR-B) announced today that the Russian Ministry of Health has approved Sovriad(R) (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

Help employers find you! Check out all the jobs and post your resume.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES